Tin nóng
Evolocumab in High-Risk Primary Prevention: Is Earlier Intervention Warranted in Diabetes?
In a subgroup analysis of the VESALIUS-CV trial found that Evolocumab reduces the risk of a first major cardiovascular event in high-risk patients with diabetes
